Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients. Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study)

Atherosclerosis

Volumn 201, Issue 2, 2008, Pages 345-352

  Yokote, Koutaro ^a   Bujo, Hideaki ^a   Hanaoka, Hideki ^b   Shinomiya, Masaki ^c   Mikami, Keiji ^d   Miyashita, Yoh ^e   Nishikawa, Tetsuo ^f   Kodama, Tatsuhiko ^g   Tada, Norio ^h   Saito, Yasushi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c Nishifuna Naika   (Japan)

^d Omigawa General Hospital   (Japan)

^e National Hospital Organization   (Japan)

^f YOKOHAMA ROSAI HOSPITAL   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatic enzymes; Metabolic syndrome; Non HDL cholesterol; Obesity; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; TRIACYLGLYCEROL;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BODY MASS; BODY SIZE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; JAPAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT RESPONSE; WAIST CIRCUMFERENCE;

AGED; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; JAPAN; MALE; MIDDLE AGED; PYRROLES; QUINOLINES; WAIST CIRCUMFERENCE;

EID: 56649111325     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.02.008     Document Type: Article

References (28)

1. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
3. Lu W., Resnick H.E., Jablonski K.A., et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 26 (2003) 16-23
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
5. CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
6. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
7. Saito Y., Yamada N., Teramoto T., et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 52 (2002) 251-255
8. Sone H., Takahashi A., Shimano H., et al. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci 71 (2002) 2403-2412
9. Saito Y., Yamada N., Teramoto T., et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolaemia. Atherosclerosis 162 (2002) 373-379
10. Fujino H., Yamada I., Shimada S., Nagao T., and Yoneda M. Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Arzneimittelforschung 52 (2002) 745-753
11. Fujino H., Nakai D., Nakagomi R., Saito M., Tokui T., and Kojima J. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung 54 (2004) 382-388
12. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. Circ J 2002;66:987-92.
13. Committee for Japanese Definition of Metabolic Syndrome. Metabolic syndrome-definition and diagnostic criteria in Japan. J Jpn Soc Intern Med 94 (2005) 794-809 [in Japanese]
14. Kuzuya T, Nakagawa S, Satoh J, et al. Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002; 55:65-85.
15. Teramoto T., Saito Y., Yamada N., et al. Clinical safety and efficacy of NK-104 (Pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the long-term treatment of hyperlipidemia-results of a multicenter long-term study. Clin Ther Med 17 (2001) 885-913 [in Japanese]
16. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. Clinical effect of the novel HMG-CoA reductase inhibitor CI-981 (atorvastatin) in long-term treatment. Prog Med 19 (1999) 2123-2160 [in Japanese]
17. Bittner V. Non-high-density lipoprotein cholesterol: an alternate target for lipid-lowering therapy. Prev Cardiol 7 (2004) 122-126
18. Stalenhoef A.F., Ballantyne C.M., Sarti C., et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 26 (2005) 2664-2672
19. MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368 (2006) 1155-1163
20. Maejima T., Yamazaki H., Aoki T., et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 324 (2004) 835-839
21. Saiki A., Murano T., Watanabe F., Oyama T., Miyashita Y., and Shirai K. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 12 (2005) 163-168
22. Hanyu O., Miida T., Obayashi K., et al. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 174 (2004) 385-390
23. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
24. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol 97 (2006) 1553-1557
25. Ando H., Tsuruoka S., Yanagihara H., et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 60 (2005) 494-497
26. Morikawa S., Umetani M., Nakagawa S., et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 7 (2000) 138-144
27. Egawa T., Toda K., Nemoto Y., et al. Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice. Lipids 38 (2003) 519-523
28. Miyauchi K., Kimura T., Morimoto T., et al. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design. Circ J 70 (2006) 1624-1628